Summit Wealth & Retirement Planning’s Aquestive Therapeutics AQST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$139K Sell
30,000
-5,000
-14% -$22.2K 0.03% 109
2026
Q2
$146K Hold
35,000
– – 0.03% 112
2026
Q1
$145K Buy
35,000
+20,000
+133% +$81.2K 0.03% 107
2025
Q4
$96.9K Hold
15,000
– – 0.02% 110
2025
Q3
$83.8K Buy
15,000
+5,000
+50% +$21.6K 0.02% 104
2025
Q2
$33.1K Hold
10,000
– – 0.01% 101
2025
Q1
$29K Buy
+10,000
New +$30.3K 0.01% 78

Other funds holding AQST

Summit Wealth & Retirement Planning's AQST Position: Q3 2026 in Review

Summit Wealth & Retirement Planning reduced its Aquestive Therapeutics (AQST) stake by 14% in Q3 2026, selling an estimated $22.2K and leaving 30,000 shares worth $139K. The position accounts for 0.03% of the portfolio, ranked #109.

Summit Wealth & Retirement Planning first reported a position in AQST in Q1 2025 and has held it in 7 quarters since. The position peaked at $146K in Q2 2026. 190 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • Summit Wealth & Retirement Planning held 30,000 shares of Aquestive Therapeutics worth $139K as of Q3 2026.
  • Summit Wealth & Retirement Planning sold 5,000 Aquestive Therapeutics shares in Q3 2026, an estimated $22.2K.
  • Aquestive Therapeutics made up 0.03% of Summit Wealth & Retirement Planning's portfolio in Q3 2026, its #109 holding.
  • Summit Wealth & Retirement Planning first reported a position in Aquestive Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Summit Wealth & Retirement Planning's Aquestive Therapeutics position peaked at $146K in Q2 2026.
  • 190 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Summit Wealth & Retirement Planning's 13F filing for Q3 2026, filed 12 Nov 2026.